Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Neuropathy;Peripheral
- Sponsor
- M.D. Anderson Cancer Center
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
- Status
- Active, Not Recruiting
- Last Updated
- 5 months ago
Overview
Brief Summary
To learn if a process called neuromodulation can help to improve pain due to CIP
Detailed Description
Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document * Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds * Patients seen at Pain Management Center at MD Anderson Cancer Center * Patient ages greater or equal to 18 years but less than or equal to 85 years Exclusion Criteria: * Patients with cognitive dysfunction * Patient with recent history (\<6 months) of drug or alcohol abuse * Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection * Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy
Investigators
Eligibility Criteria
Inclusion Criteria
- •Ability to understand and the willingness to sign a written informed consent document
- •Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds
- •Patients seen at Pain Management Center at MD Anderson Cancer Center
- •Patient ages greater or equal to 18 years but less than or equal to 85 years
- •Exclusion Criteria
- •Patients with cognitive dysfunction
- •Patient with recent history (\<6 months) of drug or alcohol abuse
- •Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection
- •Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Time Frame: through study completion; an average of 1 year.